Julian Symons
Direttore Tecnico/Scientifico/R&S presso ALIGOS THERAPEUTICS, INC.
Patrimonio netto: 322 344 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Lawrence Blatt | M | 62 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 13 anni |
| Lucinda Quan | F | 51 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 10 anni |
| Carole Nüchterlein | F | 62 | 6 anni | |
| K. Hirth | M | 72 | 6 anni | |
| Jim Scopa | M | 65 | 3 anni | |
| Bridget Martell | M | 58 | 3 anni | |
| Jordyn Tarazi | F | - | - | |
| Sushmita M. Chanda | M | 58 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 14 anni |
| Lesley Calhoun | F | 58 | 4 anni | |
| Kristina Engeseth | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jack Nielsen | M | 60 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 13 anni |
| Leonid Beigelman | M | 66 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 anni |
| John Fry | M | - |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 anni |
| Kathleen Glaub | F | 70 | - | |
| Peter Moldt | M | 65 | - | |
| Thomas Woiwode | M | 52 | 5 anni | |
| Matthew McClure | M | 53 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 anni |
| Heath Lukatch | M | 56 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 5 anni |
| Carol Brosgart | M | 72 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | - |
| Rosanne Roth | F | - |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 3 anni |
| Sunny Lee Ryan | F | 54 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 21 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Julian Symons
- Contatti personali
